According to a new publication published online in the journal ACS infectious disease, a group of long-recommended medicines for the treatment of tapeworms has encouraged a compound that shows two-way effectiveness against coved19.
The compound, part of a class of molecules called salicylanolides, was designed in the laboratory by Prof. Kim Janda, Ph.D., Ellie r. Callaway, director of the verm institute for research and medicine at junior Prof. Of chemistry and scrips research La Jolla, ca
"It has been known for 10 or 15 years that salicylates work against certain viruses," says Janda. "However, they restrict the intestines and may have toxic problems."
Janda's compound controls both problems in mouse and cell-based tests, ACTS as an antiviral and anti-inflammatory drug, with properties that grow well for its use in the form of a tablet.
Salicylanylides were first discovered in Germany in the 1950s and used to deal with insect infections in livestock. Versions of drugs, including niclosamide, are now used to treat tapeworms in animals and humans. They have also been studied for anti-cancer and bacteriological properties.
The revised salicylamide compound, made by Janda, was one of about 60 years ago for another project. When the sars-Nov-2 virus became a global epidemic in early 2020, knowing that it had anti-viral properties, it started screening its old collection, first with colleagues from Sorrento pharmaceutics and the University of Texas medical branch, and later, seeing promising results while working with scraps research immunologist John Tejano, Ph.D., who studied rat.
A compound stood outside. Dubbed "no. 11," it differs in important ways from commercial tap-worm drugs, including its ability to pass through its intestines and absorb into the bloodstream - and without any worrisome toxins.
"Neclosamide is mainly restricted to the digestive tract, and it makes sense because parasites live here," says Janda. "For that reason, the simple drugs used again to treat coveted will be contradictory because you want something that is bioavailable, yet there is no systemic toxicity that niclosamide has."
Janda says about 80% of salicylamide 11 entered the bloodstream, compared to 10% of the antiparasitic drug niclosamide, which has recently entered clinical trials as a treatment for coved19.
Experiments show that no. 11 of several modified salicylenoids made in its laboratory affected epidemic coronavirus infection in two ways. First, it interfered with how a virus collects its genetic material into infected cells, a process called endocytosis. For endocytosis, viruses must form a lipid-based packet around the viral gene. The packet enters and dissolves into the infected cell, so the protein-making machinery of the affected cell can read it and remove new viral copies. The number 11 appears to inhibit the dissolution of the packet.
"The anti-viral mechanism of the compound is the key," says Janda. "It prevents viral content from exiting the endosome, and it only worsens. This process doesn't let new viral particles become so easily."
The important thing is that since it works inside cells instead of viral spikes, questions about whether it will work in new varieties like delta and lambda, no worries, he added.
"This mechanism does not depend on virus spike proteins, so these new shapes won't lead us to find new molecules as is the case with vaccines or antibodies," Janda says.
In addition, no. 11 helped reduce the potentially poisonous inflammation in research animals; Janda says it can be important to treat severe respiratory problems associated with life-threatening covid infections. It reduced the level of interleukin 6, a signaling protein that is a key adjunctive to inflammation commonly found in the modern stages of coved19.
Improved medication is urgently needed against covid-19, as highly infectious new forms of disease and death resurgence globally. But Janda says salicylamide no. 11 was created long before the epidemic.
It saw a clear need for better treatment options after fighting an unpleasant bacterial infection named clostridium Ufficiale 10 years ago; it saw a clear need for better treatment options. Multiple-drug strains of c diphenyl have become a major cause of drug-resistant diarrhea outbreaks in global health care institutions and people using antibiotics, as director of the film institute, which focused on parasitic infections, and was very familiar with salicysalinylides and knew about their antimicrobial properties. Its laboratory created a "library" of modified salicylanolides, many of which showed strong efficacy against c divisible, and the combination was later licensed by the pharmaceutical firm Sorrento therapeutics. Among them was salicylamide 11.
"Salicylanelide 11 was actually placed on the back burner in my laboratory against c-feasible because it is not limited to the gut as we want," Janda says. "But salicylamide 11 has got a lot of positive things going for him as a possible cure for covid."
You must be logged in to post a comment.